Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,717 Mln
Revenue (TTM)
$4,023 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
0.2 %
P/E Ratio
--
P/B Ratio
2.4
Industry P/E
--
EV/EBITDA
19.2
Div. Yield
0 %
Debt to Equity
0.8
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
49,115,700
CFO
$4,684.98 Mln
EBITDA
$5,674.98 Mln
Net Profit
$2,748.66 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Charles River Laboratories (CRL)
| -16.6 | 6.4 | 12.4 | -22.9 | -12.0 | -3.3 | 8.2 |
|
BSE Sensex*
| 7.0 | 1.9 | 14.5 | 4.6 | 15.6 | 17.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Charles River Laboratories (CRL)
| -21.8 | 8.5 | -42.2 | 50.8 | 63.6 | 35.0 | 3.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Charles River Laboratories (CRL)
|
153.9 | 7,717.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.4 |
| 51.5 | 8,330.6 | 1,208.8 | 131.7 | 13.4 | 6.3 | 64 | 4.1 | |
| 128.4 | 8,299.9 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 52.5 | 10,065.7 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 44.2 | 12,585.5 | 2,298.9 | 643.6 | 35.4 | 29.2 | 21.1 | 5.9 | |
| 41.8 | 6,843.8 | 717.4 | -458.0 | -59.5 | -80.5 | -- | 14.4 | |
| 318.9 | 9,240.4 | 2,156.6 | 416.4 | 21.2 | 56.5 | 24.6 | 15.6 | |
| 29.9 | 11,791.8 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.2 | |
| 127.9 | 12,777.5 | 2,412.6 | 305.8 | 20.5 | 11.6 | 43.9 | 5.0 | |
| 290.4 | 13,283.4 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.7 | 2.0 |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research... Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Read more
Chairman, CEO & President
Mr. James C. Foster J.D.
CEO, President & Chairman
Mr. James C. Foster J.D.
Headquarters
Wilmington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Charles River Laboratories (CRL) stood at $ 8,633 Mln as on 31-Mar-25
The share price of Charles River Laboratories (CRL) is $153.90 (NYSE) as of 07-Jul-2025 16:10 EDT. Charles River Laboratories (CRL) has given a return of -12.02% in the last 3 years.
Charles River Laboratories (CRL) has a market capitalisation of $ 7,717 Mln as on 03-Jul-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Charles River Laboratories (CRL) is 2.42 times as on 03-Jul-2025, a 19% discount to its peers’ median range of 2.97 times.
Since, TTM earnings of Charles River Laboratories (CRL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Charles River Laboratories (CRL) and enter the required number of quantities and click on buy to purchase the shares of Charles River Laboratories (CRL).
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
The CEO & director of Mr. James C. Foster J.D.. is Charles River Laboratories (CRL), and CFO & Sr. VP is Mr. James C. Foster J.D..
There is no promoter pledging in Charles River Laboratories (CRL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,332
|
|
|
1,281
|
|
|
1,208
|
|
|
1,171
|
|
|
1,016
|
|
|
937
|
|
|
834
|
|
|
829
|
|
|
694
|
| Charles River Laboratories (CRL) | Ratios |
|---|---|
|
Return on equity(%)
|
-1.08
|
|
Operating margin(%)
|
3.71
|
|
Net Margin(%)
|
-0.78
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Charles River Laboratories (CRL) was $0 Mln.
$-3.22
(
